Synergy Pharmaceuticals Inc

Synergy Pharmaceuticals — Investor Presentation (December 2011)

27 slides from Synergy Pharmaceuticals's investor presentation, Dec 27, 2011

  1. Slide 1: Corporate Presentation December 2011

    Corporate Presentation December 2011 PK

  2. Slide 2: Forward-Looking Information

    Certain statements made in this presentation are forward-looking. Such statements are indicated by words such as “expect,” “should,” “anticipate” and similar words indicating uncertainty in facts and figures. Although Synergy believes that the expectations reflected in such forward-looking statement

  3. Slide 3: Investment Highlights

    Investment Highlights Proprietary Technology Targeted therapy – specific selective receptors in GI tract Proprietary (Guanylate Cyclase-C) GC-C Receptor Agonists Control 100% of worldwide commercial rights “Plecanatide” to treat Chronic Constipation (Phase II/III Trial Underway – Oct. 2011) and Cons

  4. Slide 4: Management Team

    Gary S. Jacob, Ph.D.; President, CEO Over 25 years of experience in pharmaceutical and biotechnology industries across multiple disciplines including: research & development, operations and business development G.D. Searle/Monsanto Co., Oxford University Kunwar Shailubhai, Ph.D., MBA; Chief Scientif

  5. Slide 5: Plecanatide is a $2bn Market Opportunity

    Plecanatide is a $2bn Market Opportunity (1) >100mm people worldwide suffer from CC / IBS-C 15% of U.S. population or ~45mm people High incidence of severe form 20mm in U.S., Europe & Japan 6.0 - 8.5mm patients in U.S. with CC sought medical care in 2007 Widespread belief amongst physicians that sev

  6. Slide 6: CC / IBS-C Landscape

    CC / IBS-C Landscape Sucampo & Takeda annual reports, Movetis annual report, Ladenburg Thalmann research report, press releases. Amitiza® Resolor® Linaclotide Only late-stage drug currently in development in U.S. Indication Stage Mechanism of Action (MOA) Most Common Side Effect(s) Sales1 Commentary

  7. Slide 7: Mechanism of Action

    Mechanism of Action Clinical Data Regulatory & Clinical Plan Intellectual Property Competitive Positioning

  8. Slide 8: Guanylate Cyclase C Receptor Agonists

    Guanylate Cyclase C Receptor Agonists Physiological mechanism Cross section of the GI tract Activation of GC-C receptors stimulates synthesis of cyclic GMP, activating cystic fibrosis transmembrane conductance regulator (CFTR) Activated CFTR secretes Cl-, HCO3- and fluid into the intestinal lumen. S

  9. Slide 9: Plecanatide – A Superior Analogue of Uroguanylin

    Plecanatide – A Superior Analogue of Uroguanylin 16-mer analogue of natural uroguanylin Single key amino acid change Locked into stable active conformer Compact stable molecule Thermo and acid stable (100 °C, pH 2) High resistance to proteases Behaves like a small molecule drug More potent than the

  10. Slide 10: Clinical Data

    Mechanism of Action Clinical Data Regulatory & Clinical Plan Intellectual Property Competitive Positioning

  11. Slide 11: Completed Phase IIa Trial Design

    Four dose cohorts in trial: Placebo (plecanatide at 0.3, 1.0, 3.0 or 9.0 mg) QD in the a.m. for 14 days 20 subjects per dose cohort, 3:1 randomization Protocol Design Completed Phase IIa Trial Design Days -28 to -14 Days -14 to -1 Day 1 to Day 7 (+/- 1 day) Day 21 (+/- 3 days) Screening Pre-Treatmen

  12. Slide 12: Phase IIa Safety Findings

    Demographics: Primarily females (>80%) of Caucasian descent with mean age per cohort ranging from 47 to 51 years old (1) No detectable systemic absorption of plecanatide Assay sensitivity >10 ng/mL No serious adverse events (SAE) reported in subjects receiving plecanatide No deaths reported in this

  13. Slide 13: Phase IIa Study Findings and Conclusions

    Phase IIa Study Findings and Conclusions More than 50% of patients on plecanatide had 1st bowel movement within 7 hours vs. 16 hours for placebo Plecanatide also demonstrates increase in number of spontaneous and complete spontaneous bowel movements Median Time to First Bowel Movement after Administ

  14. Slide 14: Phase IIa Study Findings and Conclusions (Cont'd)

    Phase IIa Study Findings and Conclusions (Cont’d) Other endpoints such as complete spontaneous bowel movements (CSBM) and straining scores are improved following treatment with plecanatide Change from Baseline in Complete Spontaneous Bowel Movements (CSBM) Change from Baseline in Straining Scores 0.

  15. Slide 15: Phase IIa Secondary Endpoints

    Other key secondary endpoints including abdominal discomfort, constipation severity and overall relief are also improved following the 14-day treatment with plecanatide Patient Global Assessment Abdominal Discomfort Patient Global Assessment Constipation Severity Patient Global Assessment Overall Re

  16. Slide 16: Plecanatide Clinical Summary: Efficacy in CIC

    Plecanatide Clinical Summary: Efficacy in CIC Consistent with GC-C Receptor Agonists Increases the number of CSBMs & SBMs/week Doses > 1 mg resulted in 50% of patients experiencing their 1st bowel movement within 7 hours vs. 16 hours for placebo Improves straining scores, stool consistency, abdomina

  17. Slide 17: Regulatory & Clinical Plan

    Mechanism of Action Clinical Data Regulatory & Clinical Plan Intellectual Property Competitive Positioning

  18. Slide 18: Phase II/III Trial Status – Enrollment Underway

    A Phase II/III trial for patients with chronic idiopathic constipation Four treatment arms: Oral plecanatide (0.3 mg, 1.0 mg, 3.0 mg) QD or matching placebo Approximately 880 total subjects (1:1:1:1 randomization) Protocol Design Phase II/III Trial: Status – Enrollment Underway Days -35 to -15 Days

  19. Slide 19: Phase II/III Study Objectives

    Phase II/III Study Objectives Evaluate efficacy of once daily oral dosing of plecanatide (0.3 mg, 1.0 mg and 3.0 mg) Complete spontaneous bowel movements (CSBM) – using responder analyses (> 3 CSBMs/wk with increase of > 1CSBM/wk) (FDA mandated) Primary Objective Secondary Objectives Spontaneous bow

  20. Slide 20: Near-Term Milestones and Value Catalysts

    Near-Term Milestones Value Catalysts Began Phase II/III trial in October, 2011; Increased awareness within GI Community Key IP include plecanatide "composition of matter" patents in U.S., EU; and SP-333 U.S. “composition-of-matter” patent issued in 2011 Control 100% of worldwide rights Plecanatide p

  21. Slide 21: Capitalization

    Capitalization Capitalization (12/27/11) Shares Outstanding % Outstanding Common Stock 53,953,675 84.3% Stock Options (Average Strike of $1.23) 4,464,039 7.0% Warrants (Average Strike of $5.67) 5,597,203 8.7% Fully-diluted Shares Outstanding 64,014,917 100.0%

  22. Slide 22: Intellectual Property

    Mechanism of Action Clinical Data Regulatory & Clinical Plan Intellectual Property Competitive Positioning

  23. Slide 23: Intellectual Property

    Intellectual Property IP Position Key U.S. Composition-of-Matter Patent Patent No. U.S. 7,041,786 Issue Date May 9, 2006 Title Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis Inventors K. Shailubhai, G. Nikiforovich, G. Jacob Assignee Synergy Pharmaceu

  24. Slide 24: Investment Highlights

    Investment Highlights Proprietary Technology Targeted therapy – specific selective receptors in GI tract Proprietary (Guanylate Cyclase-C) GC-C Receptor Agonists Control 100% of worldwide commercial rights “Plecanatide” to treat Chronic Constipation (Phase II/III Trial Underway – Oct. 2011) and Cons

  25. Slide 25: Appendix

    Appendix

  26. Slide 26: SP-333 - Synergy's Second GC-C Receptor Agonist

    SP-333 - Synergy’s Second GC-C Receptor Agonist “2nd-generation” GC-C agonist drug for ulcerative colitis (UC) GC-C agonists exhibit potent anti-inflammatory activity in animal models of inflammation Novel mechanism-of-action SP-333 to treat Ulcerative Colitis, an Irritable Bowel Disease (IBD) Key H

  27. Slide 27: Board of Directors

    Board of Directors Gabriele Cerrone, Chairman Founder of number of biotechnology and diagnostic companies: FermaVir, Inc. (Acquired by Inhibitex, Inc.) SIGA Technologies, Inc. Synergy Pharmaceuticals, Inc. Trovagene, Inc., a molecular diagnostic company Callisto Pharmaceuticals, Inc. Managing partne

Synergy Pharmaceuticals — Investor Presentation (December 2011) on 6ix